课题基金 / 基金详情

SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY

SANDOSTATIN LAR IN PATIENTS W/ ACROMEGALY
善宁 LAR 用于肢端肥大症患者
批准号：
6264648
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264648
关键词：
acromegaly clinical research drug screening /evaluation endocrine disorder chemotherapy hormone regulation /control mechanism human subject human therapy evaluation insulinlike growth factor octreotide quality of life somatostatin somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
这项IIIb期、开放标签临床试验试图证明善得定LAR（一种长效奥瑞肽）获得和/或维持正常化IGF-1水平的能力。 该试验希望达到其他目的，包括记录Sandostatin LAR获得和/或维持治疗GH水平的能力，以及缓解肢端肥大症的临床体征和症状。 还将评估生活质量问题。
英文摘要
This Phase IIIb, open-label clinical trial attempts to document the ability of Sandostatin LAR, a long-acting ocreotide, to obtain and/or maintain normalized IGF-1 levels. The trial hopes to acheive other objectives including documentation of Sandostatin LAR 's ability to obtain and/or maintain therapeutic GH levels, and to relieve clinical signs and symptoms of acromegaly. Quality of life issues will also be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金